• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Research Tie Ups Might Change The Case For Investing In Oxford Nanopore Technologies (LSE:ONT)

    Simply Wall St·11/10/2026 08:29:56
    Listen to the news
    • Oxford Nanopore Technologies has featured in positive analyst commentary on BioPharma and Clinical revenue opportunities, AI use on rich sequencing datasets, and recent legal outcomes, while also presenting at the Stifel 2026 Healthcare Conference and gaining visibility with CFO Nicholas Patrick Keher speaking.
    • The University of California San Diego Center for Microbiome Innovation and the BRIC-CDFD–ONT India Genomics Centre of Excellence both selected Oxford Nanopore platforms for high throughput research, signaling real world adoption of its sequencing technology across microbiome and genomics programs.
    • Next, the focus will shift to how Oxford Nanopore Technologies' expanding research collaborations could influence the broader investment narrative and risk profile.

    Scan beyond Oxford Nanopore Technologies and line up other genomics and AI-enabled opportunities using our hand picked list of 9 healthcare AI stocks that are poised for real world healthcare adoption.

    What Is Oxford Nanopore Technologies' Investment Narrative?

    To own Oxford Nanopore Technologies, you need to believe its sequencing platforms can turn growing research traction into a durable, higher margin tools business even while the group remains loss making. The UC San Diego microbiome partnership and the BRIC CDFD India Genomics Centre of Excellence show that real world users are committing to PromethION systems, which supports demand for instruments and consumables. Analyst commentary around BioPharma and Clinical opportunities plus AI use on data gives extra optionality, but the operational story still hinges on consistent execution in labs, not conference soundbites.

    The Stifel 2026 Healthcare Conference slot for CFO Nicholas Patrick Keher matters mainly as a chance to reset expectations on cash burn, capital needs and the path from £235.0m of revenue and a £121.4m loss toward better unit economics. In the short term, the bigger levers remain pricing discipline, utilization of installed platforms and how quickly collaborations translate into recurring consumables spend. Forecast revenue growth of 16.2% a year and a DCF estimate above the current £2.10 share price frame the upside narrative. The flip side is a volatile share price, rich P/S multiples and no forecast profitability over the next three years, which keep execution risk very real.

    That said, tucked behind the excitement around AI and new genomics centres is a quieter issue that could yet reshape the Oxford Nanopore story if...

    There's only one way to know the right time to buy, sell or hold Oxford Nanopore Technologies. Head to Simply Wall St's company report for the latest analysis of Oxford Nanopore Technologies's Fair Value.

    LSE:ONT 1-Year Stock Price Chart
    LSE:ONT 1-Year Stock Price Chart

    Exploring Other Perspectives

    Two fair value estimates from the Simply Wall St Community span roughly £2.17 to £3.23, so even retail models are not singing from the same hymn sheet on Oxford Nanopore Technologies. You are seeing that diversity ahead of the Stifel 2026 conference and before new genomics partnerships filter through, which invites you to compare several alternative viewpoints.

    Explore another Oxford Nanopore Technologies fair value estimate, including one that suggests there could be as much as 54% upside from the current price.

    Reach Your Own Conclusion

    Do not just follow the ticker; dig into the data and build a conviction that is truly your own.

    Looking For More Investment Ideas Beyond Oxford Nanopore Technologies?

    If you want to widen your watchlist beyond Oxford Nanopore Technologies, a targeted screener can help you quickly filter the market to fit your risk tolerance, income needs, and valuation discipline.